Table 2.
Main clinical features in anti-LGI1 encephalitis.
| Total | |
|---|---|
| n/N (%)a | |
| Short-term memory loss | 349/464 (75.22%) |
| Psychiatric symptoms | 124/215 (57.67%) |
| FBDS | 135/257 (52.53%) |
| Other seizures excluding FBDS | 176/257 (68.48%) |
| Sleep disturbances | 106/309 (34.30%) |
| Confusion | 27/100 (27.00%) |
| Hyponatremia | 196/357 (54.90%) |
| Hyper intensity in the medial temporal lobe or hippocampus in MRI (T2 / FLAIR) | 279/380 (73.42%) |
| High metabolism in the medial temporal lobe or hippocampus in PET | 30/43 (69.77%) |
| Positive rate of anti-LGI1 in serum | 244/252 (96.83%) |
| Positive rate of anti-LGI1 in CSF | 171/221 (77.38%) |
| Positive rate of anti-LGI1 in both serum and CSF | 139/197 (70.56%) |
FBDS, faciobrachial dystonic seizures; CSF, cerebrospinal fluid.
a
Data reported as n/N (%), where N is the total number of patients with details applicable for each feature and n is the number of patients presenting features.